107 related articles for article (PubMed ID: 37995981)
1. TET1 regulates stem cell properties and cell cycle of Cancer stem cells in triple-negative breast cancer via DNA demethylation.
Ghazimoradi MH; Pakravan K; Khalafizadeh A; Babashah S
Biochem Pharmacol; 2024 Jan; 219():115913. PubMed ID: 37995981
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
3. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
[TBL] [Abstract][Full Text] [Related]
4. Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells.
Wang W; Li X; Wang F; Sun XY
J Cell Biochem; 2018 Jan; 119(1):723-735. PubMed ID: 28643947
[TBL] [Abstract][Full Text] [Related]
5. Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer.
Bao B; Teslow EA; Mitrea C; Boerner JL; Dyson G; Bollig-Fischer A
Mol Cancer Res; 2020 Dec; 18(12):1803-1814. PubMed ID: 32913111
[TBL] [Abstract][Full Text] [Related]
6. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
Umeh-Garcia M; O'Geen H; Simion C; Gephart MH; Segal DJ; Sweeney CA
Br J Cancer; 2022 Aug; 127(3):436-448. PubMed ID: 35440669
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Mediated Epigenetic Regulation of Stemness in Brain Tumor Cells.
Prasad P; Mittal SA; Chongtham J; Mohanty S; Srivastava T
Stem Cells; 2017 Jun; 35(6):1468-1478. PubMed ID: 28376560
[TBL] [Abstract][Full Text] [Related]
9. 3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.
Peng X; Chang H; Chen J; Zhang Q; Yu X; Mi M
BMC Cancer; 2017 Sep; 17(1):619. PubMed ID: 28870206
[TBL] [Abstract][Full Text] [Related]
10. TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma cells.
Fan J; Zhang Y; Mu J; He X; Shao B; Zhou D; Peng W; Tang J; Jiang Y; Ren G; Xiang T
Clin Epigenetics; 2018 Aug; 10(1):103. PubMed ID: 30075814
[TBL] [Abstract][Full Text] [Related]
11. miR-646/TET1 mediated demethylation of IRX1 promoter upregulates HIST2H2BE and promotes the progression of invasive ductal carcinoma.
He B; Chen J; Song W; Bai Y
Genomics; 2021 May; 113(3):1469-1481. PubMed ID: 33667646
[TBL] [Abstract][Full Text] [Related]
12. A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer.
Good CR; Madzo J; Patel B; Maegawa S; Engel N; Jelinek J; Issa JJ
Nucleic Acids Res; 2017 Aug; 45(14):8269-8281. PubMed ID: 28531272
[TBL] [Abstract][Full Text] [Related]
13. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases.
Hsu CH; Peng KL; Kang ML; Chen YR; Yang YC; Tsai CH; Chu CS; Jeng YM; Chen YT; Lin FM; Huang HD; Lu YY; Teng YC; Lin ST; Lin RK; Tang FM; Lee SB; Hsu HM; Yu JC; Hsiao PW; Juan LJ
Cell Rep; 2012 Sep; 2(3):568-79. PubMed ID: 22999938
[TBL] [Abstract][Full Text] [Related]
14. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
Wang K; Chen Z; Shi J; Feng Y; Yu M; Sun Y; Zhuang Q; Liang B; Luo G; Xu X; Fan M
Prostate; 2020 Sep; 80(12):977-985. PubMed ID: 32542727
[TBL] [Abstract][Full Text] [Related]
16. UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
Li J; Liang Y; Zhou S; Chen J; Wu C
Breast Cancer Res; 2024 Mar; 26(1):44. PubMed ID: 38468288
[TBL] [Abstract][Full Text] [Related]
17. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression.
Pei YF; Tao R; Li JF; Su LP; Yu BQ; Wu XY; Yan M; Gu QL; Zhu ZG; Liu BY
Oncotarget; 2016 May; 7(21):31322-35. PubMed ID: 27121319
[TBL] [Abstract][Full Text] [Related]
18. Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2.
Li M; Tang Y; Li Q; Xiao M; Yang Y; Wang Y
Oncogene; 2019 May; 38(18):3488-3503. PubMed ID: 30651599
[TBL] [Abstract][Full Text] [Related]
19. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
[TBL] [Abstract][Full Text] [Related]
20. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
